Early Life and Education
Christian Angermayer was born on April 26, 1978, in Wiesau, Bavaria, West Germany. In 1998, he enrolled at the University of Bayreuth to study biochemistry, where he met professors Roland Kreutzer and Stefan Limmer. They were working on a gene-targeting technology called RNA interference, leading Angermayer to co-found Ribopharma AG in 2000. Although he only held a minority stake, Ribopharma received backing from the German government, enabling him to drop out of college.
Rise to Success
Ribopharma merged with Alnylam Pharmaceuticals in 2003. Since then, Angermayer has created, co-founded, and invested in numerous successful companies, raising over $2 billion for his portfolio companies and participating in more than 50 IPO and M&A transactions. He founded Apeiron Investment Group, his family office, which manages approximately $7 billion. Angermayer has been a pioneer in the cryptocurrency industry and has been behind many flashy investments. He is the founder of the biotechnology company atai Life Sciences.
Key Business Strategies
Angermayer focuses on investments in life sciences, fintech, AI, psychedelics, and cryptocurrencies. He aims to promote technologies aimed at extending human healthspan and well-being. Angermayer is a prominent proponent of the "psychedelic renaissance" in medicine, arguing for the therapeutic potential of psychedelic compounds in mental-health treatment. He is known for his ability to connect with people and has built a strong network of contacts. Apeiron Investment Group uses a global, multi-strategy investment approach, focusing primarily on the U.S. market.
Philanthropy
Christian Angermayer is involved in philanthropic efforts, particularly in mental health awareness and research.
